Browsing Tag
faridoxorubicin
3 posts
Avacta Therapeutics (AIM: AVCT) reports 90% disease control rate in faridoxorubicin salivary gland cancer trial
Avacta Therapeutics’ AVA6000 trial shows a 90% disease control rate in salivary gland cancer. Find out how its tumor-activated approach could reshape chemotherapy.
December 22, 2025
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.
October 21, 2025
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises £16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
October 20, 2025